Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jul 28;18(7):e0288904. doi: 10.1371/journal.pone.0288904

A comparative study to optimize experimental conditions of pentylenetetrazol and pilocarpine-induced epilepsy in zebrafish larvae

David Szep 1,2, Bianka Dittrich 1,2, Aniko Gorbe 1,2, Jozsef L Szentpeteri 1, Nour Aly 2, Meng Jin 3, Ferenc Budan 1,2,#, Attila Sik 1,2,4,*,#
Editor: Giuseppe Biagini5
PMCID: PMC10381053  PMID: 37506089

Abstract

A common way to investigate epilepsy and the effect of antiepileptic pharmaceuticals is to analyze the movement patterns of zebrafish larvae treated with different convulsants like pentylenetetrazol (PTZ), pilocarpine, etc. Many articles have been written on this topic, but the research methods and exact settings are not sufficiently defined in most. Here we designed and executed a series of experiments to optimize and standardize the zebrafish epilepsy model. We found that during the light and the dark trials, the zebrafish larvae moved significantly more in the light, independent of the treatment, both in PTZ and pilocarpine-treated and the control groups. As expected, zebrafish larvae treated with convulsants moved significantly more than the ones in the control group, although this difference was higher between the individuals treated with PTZ than pilocarpine. When examining the optimal observation time, we divided the half-hour period into 5-minute time intervals, and between these, the first 5 minutes were found to be the most different from the others. There were fewer significant differences in the total movement of larvae between the other time intervals. We also performed a linear regression analysis with the cumulative values of the distance moved during the time intervals that fit the straight line. In conclusion, we recommend 30 minutes of drug pretreatment followed by a 10-minute test in light conditions with a 5-minute accommodation time. Our result paves the way toward improved experimental designs using zebrafish to develop novel pharmaceutical approaches to treat epilepsy.

Introduction

Zebrafish (Danio rerio) has widely emerged as a model organism in studies related to neuroscience [1, 2]. Despite their relatively simple nervous system, they show similarities in the development, genetic structure, and function with the mammalian nervous system [3]. The homology between zebrafish genes and human genes is higher than 70% [4, 5] with many similar functions which makes it an ideal model for drug research and central nervous system (CNS) disorders studies [4, 5]. In addition, a pair of adult fish can produce around 200 eggs a day, which can develop in a matter of hours [4], and larvae can absorb drugs directly from water [6]. The small size of zebrafish larvae makes it perfect for large-scale analysis by fitting one larva per well in a single 96-well plate [7]. In the first week of growth, they show behaviors like escaping, hunting, and negative thigmotaxis by swimming [8]. Also, they can react to visual and acoustic stimuli [9]. As zebrafish larva starts to feed at 5 days post fertilization (dpf) [10] and according to regulations the nonfeeding larva is not considered an animal, thus ethical permit is not required for performing experiments on ≤ 5dpf zebrafish larvae. Hence zebrafish larvae can be considered as a non-animal in vivo vertebrate model.

To examine the behavior of zebrafish, automated imaging techniques are frequently used. For instance, Noldus`Ethovision XT software became popular for large-scale imaging and behavioral screening. Such an approach provides precise and effective video monitoring making it easy to track motions, swimming speed, total distance traveled, and other aspects of behaviors [2, 7, 9].

Epilepsy is a CNS disorder where a large number of excitatory neurons fire in synchrony causing behavioral, neurological, and molecular changes [11]. This neurological disorder is due to an imbalance in excitation-inhibition in the CNS [2, 3]. The global prevalence of epilepsy in humans is ca. 1% [12] making this disorder one of the most common. The development of new anti-epileptic drugs (AED) is sought because one-third of patients suffering from epilepsy do not respond to existing AEDs [13].

Pentylenetetrazol (PTZ) is widely used to induce epileptiform activity in zebrafish. It is an antagonist of gamma-aminobutyric acid (GABA) inhibitory neurotransmitter with other multifarious mechanisms of action [3, 14]. The zebrafish larvae are commonly used as an epilepsy model, as they display spontaneous seizures when introduced to PTZ [4]. Different PTZ concentrations trigger locomotor activities in zebrafish larvae in various manners suggesting a non-linear PTZ-dependent fluctuation of anxiety level [15, 16]. Lower concentrations of PTZ can increase locomotion activity and high concentrations of PTZ (15 mM) cause a clonus-like convulsion that can only be reversed by some anti-epileptic drugs [2]. PTZ in 10 mM concentration is ideal for pharmacological tests and the behavioral effects of this concentration can last for approximately 16 hours [10]. The PTZ treatment under different illuminations also alters the anxiety level of zebrafish larvae differently, and the pattern of triggered movement abnormalities has not yet been investigated [3, 16]. On the other hand, pilocarpine, a muscarinic acetylcholine receptor agonist, in 30 mM concentration is another widely used drug in epilepsy research because it induces epileptiform activity that mimics closely the human temporal lobe epilepsy (TLE) [13, 14, 1720]. The effect of the pilocarpine decreases only slightly in the first 48 hours and persists up to 10 days [21], and spontaneous recurrent seizures can be seen several weeks later [11].

Details of the research methods of epilepsy model of zebrafish are often not sufficiently described [10]. Tracking time of movements and duration time of recording vary in different publications [10]. Only a few studies focused on the methodology have been published, which correlate to specific locomotion detection techniques and drug concentration [3, 10, 16]. For the zebrafish epilepsy model refinement and standardization further experiments are needed [22].

Our research aim was to test the effect of PTZ and pilocarpine on the locomotion of zebrafish larvae in light and dark environments for various recording periods to determine the optimal recording conditions. The purpose of such an optimized method is to support AED tests in the future to develop novel pharmaceutical therapeutic approaches.

Materials and methods

Adult zebrafish were kept in Tecniplast Zeb Tec System. The temperature of their water was set to 26°C, the pH to 7.5, and the conductivity to 500 μS. The conductivity level is adjusted by instant sea salt. The system automatically provided a 14-hour-long light period and a 10-hour-long dark period. The fish were fed two times a day. To produce embryos, we used wild-strain zebrafish pairs in breeding tanks. Until the experiment, the larvae were kept in egg water that was changed daily (60μg Red Sea—Coral pro sea salt in 1 ml distilled water) and was incubated at 28°C [23]. We used a total number of 270 zebrafish larvae (5 dpf), and 90 were used for each experiment. Each experiment was repeated three times. We placed the fish in 6-well plates, filled up with 5 ml of egg water, and divided them equally into three groups (30 in each): control, PTZ and pilocarpine treated. The concentrations we used for the treatment were 10 mM of PTZ [10], and 30 mM of pilocarpine [14, 18] each diluted in distilled water and egg water media for the controls. We left the fish in the solution for 30 minutes for accommodation before starting the recording [10]. We used the Noldus’ DanioVision observation chamber (Noldus Information Technology, The Netherlands), and heated the system to 28°C using the temperature control unit. After the 30-minute accommodation time, 90 fish were moved into a 96-well plate, where each well included one fish and placed the plate into the observation chamber. For recording and data collecting we used Noldus’ EthoVisionXT software (Noldus Information Technology, The Netherlands).

We performed three different experiments, and each of them contained three trials: 1) a 10-minute-long dark trial with a tapping stimulus (internal part of the Noldus system, purchased as an option) in the fifth minute, 2) the same length trial with a tapping stimulus, but performed in the light environment, 3) and a 30-minute-long trial in the light without any tapping. Between each trial, there was a 1-minute-long accommodation time, and each trial was repeated three times with each plate (Fig 1).

Fig 1. Flowchart of the research design.

Fig 1

After the trials to filter out the fish which have not been found by the software (“subjects not found” performance variable), we set up a 0.2% threshold and excluded the remaining data above this limit. After the filtering process for each experiment, we exported the total moved distance data. In the case of the whole period of the dark and the light trials, we summarized the total moved distances of each fish and used these data for further analysis. In the case of the time trials, we cumulated the distances every 5 minutes within the 30-minute-long intervals. These 5-minute periods were compared to each other individually and cumulatively. Before the statistical tests, we used outlier detection with the interquartile range method and filtered out the data as needed. Since our data distributions were not normal according to the Shapiro-Wilk normality test, for statistical analysis we performed Mann-Whitney U tests for the comparison between the groups. The significance level was set to 0.05. We also performed linear regression analysis with the cumulative values of the total moved distance data, to assess the relationship between the variables. For data analysis, we used Microsoft 365 Access, Excel, and Past 4.03 software [23].

Results

To test the effect of the light and the dark environment, we performed two 10-minute-long trials. We observed that the mean of the total distance moved by the zebrafish larvae was significantly higher (z = 3.8224; p = 0.0003) in the light trials than in the dark environment (Fig 2). Groups of larvae treated with either PTZ or pilocarpine also showed differences between the dark and light trials, thus the difference was independent of the treatment. There was a significant difference between the treatments in every combination (Table 1, Fig 3). As expected, zebrafish larvae treated with PTZ or pilocarpine moved significantly more than the ones in the control group (zcontrol-PTZ = 5380; pcontrol-PTZ = 8.65E-22; zcontrol-pilocarpine = 10473; pcontrol-pilocarpine = 6.89E-09;), although this difference was significantly higher between the individuals treated with PTZ than the ones treated with pilocarpine (Fig 4). This difference also turned out to be significant (zPTZ-pilocarpine = 6574; pPTZ-pilocarpine = 5.65E-15). We also found that the standard errors of the PTZ-treated zebrafish larvae were higher than in the case of the other two groups. Significant differences between the treatments in every combination are found. For significance values see Table 1.

Fig 2. The difference between the means of moved distances during light and dark trials (Mann-Whitney U test).

Fig 2

Table 1. Differences between the treated groups during the light and dark trials (Mann-Whitney U test).

  Light—Control Light—PTZ Light—Pilocarpine Dark—Control Dark—PTZ Dark—Pilocarpine
Light—Control - 6984 13763 14475 9734 14834
Light—PTZ 1.18E-15 - 6424 4908 9060.5 5056
Light—Pilocarpine 3.35E-05 2.63E-18 - 10280 9784 14316
Dark—Control 0.006633 1.74E-23 5.91E-12 - 7070 11253
Dark—PTZ 4.64E-10 4.20E-05 2.98E-10 1.01E-17 - 7478
Dark—Pilocarpine 0.01137 4.00E-23 0.001486 5.79E-08 1.65E-16 -

Fig 3. The means of moved distances between the treated groups during the light and dark trials.

Fig 3

Fig 4. The difference in the means of total distance moved between the PTZ, pilocarpine treated and control groups (Mann-Whitney U test).

Fig 4

We examined the optimal observation time with a 30-minute-long trial under light conditions. During the data analysis, we divided this period into 5-minute time intervals. Between the groups, the mean of the total distance moved by the PTZ-treated zebrafish larvae differed every time from every other group. However, between the control group, almost every result of the time intervals differed from the pilocarpine-treated zebrafish, except 5 times in the first 5-minutes-long interval. Within the control group, we found that the first 5-minute-long interval differed from every other significantly. On the other hand, except for the first 5 minutes, there were only three significant differences between the 5-to-10-minute interval and the last three intervals. In the case of the PTZ-treated groups`time intervals, there were only three significant differences between the first 5 minutes and the last three 5-minute-long intervals. Within the pilocarpine-treated zebrafish larvae group, the first and the second 5-minute-long interval differed significantly from every other interval and the last 5-minute-long interval, except one time. In conclusion, the first 5 minutes significantly differed from the other time intervals within the groups in all cases except two trials (Fig 5). The statistical values of the Mann-Whitney U test can be seen as supporting information (S1 Fig). Furthermore, we found significant differences in fewer numbers of cases within each treated group than between the groups (S1 Fig). When we analyzed the 5-minute-long intervals by trials, we found that there were more 5 minutes intervals in PTZ-treated groups where the zebrafish showed either hyper-activity or hypoactivity explaining the higher standard errors in this group. On the other hand, more inactive periods were observed in the control group during the first 5 minutes of the recording (Fig 6). According to the Mann-Whitney U test the first 5 minutes significantly differed from the other time intervals within the groups in all cases except two trials (also see S1 Fig)

Fig 5. Means of the total distance moved by the differently treated and control groups in 5-minute time intervals (Ncontrol = 184, NPTZ = 154, Npilocarpine = 177).

Fig 5

Fig 6. Mean of total distance moved by the differently treated and control groups during the 9 different trials.

Fig 6

We also performed a linear regression analysis with the cumulative values of the distance moved during the time intervals to assess if longer observation time could impact the difference between the groups. As seen in Fig 7 by increasing the time, the distances changed proportionally within the groups. This was supported by the linear regression analysis in most of the cases according to the R2 values (S1 Table, Fig 8).

Fig 7. Cumulative means of distance moved by PTZ, pilocarpine treated and control zebrafish groups.

Fig 7

Ncontrol = 184, NPTZ = 154, Npilocarpine = 177.

Fig 8. The regression lines calculated for PTZ, pilocarpine treated and control groups.

Fig 8

Discussion

We found that the zebrafish larvae move significantly more in the light than in the dark environment independently of the treatment. Zebrafish have diurnal activity, meaning they are more active during the day and less active at night [24], which might explain their activity under given light conditions. Previous reports described different conditions to test variations in the locomotion of zebrafish larvae [3, 15, 16, 2527]. The locomotion of the zebrafish differs under different light intensities, depending on the age of the larvae [25]. In contrast to our results, one report showed that the zebrafish moved more in the dark [15]. The reason for the difference in our finding, which is in line with other reports, PTZ increases the sensitivity to changing light environment by activating neurons, which influences the anxiety level of larvae [16]. Other results are in line with our finding: 5 days old zebrafish larvae treated with lower concentrations of PTZ (4 and 8 mM) moved less under dark conditions than under constant light. There was no difference in light and dark activity observed with the use of a higher concentration of PTZ (16 mM) [3], which can be explained by the fact that a high concentration of PTZ, specifically above 10 mM PTZ decreases swimming activity [10]. Under constant light conditions, 5 dpf zebrafish larvae treated with PTZ (8, 16 mM) showed a significant increase in locomotor activity [16]. Pilocarpine enhanced locomotor activity in continuous light. This chemical causes pupil constriction in humans [27] it may cause the same effect in zebrafish [26]. Pilocarpine could make zebrafish larvae less sensitive to light, which is in line with our results because the difference between the light and dark trials was less than the difference between the control and the PTZ-treated group. In the alternating light and dark periods, the zebrafish larvae’s movement was higher if the concentration of pilocarpine increased [28]. There was a significant difference between the dark and light trials in the control group, likely due to normal daily activity [24].

The photodegradable active pharmaceutical agents require dark experimental conditions during pharmaceutical tests [29]. The pilocarpine-induced epilepsy model performed in the dark could fulfill this requirement to examine potential photolabile AEDs.

Zebrafish larvae treated with PTZ moved significantly more than the ones treated with pilocarpine, and all of them moved more than the control group. Other authors found that pilocarpine-induced epileptiform activity and seizures were more subtle in comparison to PTZ-induced one [14, 18, 30]. Previous results show that in an acetylcholinesterase inhibitor chlorpyrifos-pretreated experimental model, 1 mM concentration of pilocarpine had a significant startle response relative to control whereas the lower concentration (100 μM) did not [31]. However, there was no significant difference in the response levels between the 100 μM and 1 mM pilocarpine doses [31]. On the other hand, the non-toxic 30 mM concentration of pilocarpine alone is suitable for movement-based pharmacological tests [13, 20].

The PTZ and the pilocarpine mechanism of action are different. PTZ is an antagonist of the GABA(A) receptor increasing the duration of the closed states of the chlorine-ion channels without influencing the conductance or duration of the open state through binding to a specific site partly overlapping with the picrotoxin binding site [32]. On the other hand, pilocarpine activates muscarinic receptor 1 (M1) causing an imbalance of inhibitory and excitatory signal transduction [33]. For example, pilocarpine elevates glutamate levels in the hippocampus after seizures and activates NMDA receptors causing increased excitation in the network [34, 35]. The differences in the mechanism of action can explain the variations we found between PTZ and pilocarpine groups.

We demonstrated that the first 5 minutes of the recording period show the largest difference in the treated groups. According to several publications, zebrafish are supposed to be left to habituate inside the tracking device for 5–10 minutes [4, 16, 30, 3640]. The habituation is an unlikely explanation for the difference in the first 5 minutes of each recording in our case because after the fish had spent the first three or six trials (40, 80 minutes) in the observation chamber, in the fourth or sixth trial we find that the first 5 minutes of the new recording is different from the other time segments. We suggest that the recording algorithm has some feature that makes the first 5 minutes of recording unreliable, and thus needs to be disregarded.

Other studies used a similar method that we used here (a 30-minute-long trial with 5 minutes intervals), but they observed an increase in the movements of the zebrafish in the first 15 minutes. The likely explanation for this discrepancy is that, unlike other research groups, we used a 30-minute-long accommodation time after the treatment and before starting the recording session [41]. According to Shaw and co-workers [10], other authors used different observation times from 2 minutes to 90 minutes. Vermoesen and colleagues [18] recorded zebrafish locomotor activity for 1 minute only, while the behavior was recorded for 18 minutes by Lopes and co-workers [30] and only 1 and 1.5 minutes were analyzed. Yang, et al. [3] used 10-minute-long trials with 5-minute-long light and dark conditions, while Peng et al. [16] used a 40-minute long light trial and three transient light-dark trials (10-minute light and 5-minute dark) and analyzed only 2-minute-long periods. The measurement of Gawel and colleagues [14] lasted for 18 minutes. Jian et al. [28] observed treated zebrafish with pilocarpine for 20 minutes, which contained a 10-minute-long light, 5-minute-long dark, and 5-minute-long light phases. The effects of the pilocarpine were observed for 8 minutes in 1-minute-long trials, then after a 24- and 96-minute intertrial interval, there were 1-minute-long trials [31]. Based on the linear regression analysis by increasing the observation period, we could see changes in the scale only, not in the differences. Because zebrafish sometimes move erratically to avoid overactive or inactive periods at least 10-minute-long intervals of observation are suggested. The 30-minute-long observation time suggested by Shaw and colleagues [10] is unnecessary. Overall, short observation time can be affected by active and inactive periods of the zebrafish larvae, while the long examination time is unnecessary unless the drug compounds tested at different time intervals provides more valuable insight [4, 39, 42].

Conclusions

We recommend a 10 minutes observation time instead of 5 minutes, as it filters out the intermittently overactive or inactive periods. If there are no special conditions, we recommend a 30-minute-long drug pretreatment followed by a 15 minutes recording of locomotion in a light environment and discard the first 5 minutes from the subsequent analysis. However, for the testing of photolabile AED compound candidates, the pilocarpine test in the dark is preferred. Our result paves the way toward improved experimental designs using zebrafish to develop novel pharmaceutical approaches to treat epilepsy. This method is a high-throughput technique, therefore it can be used to test several different combinations of AEDs within a short period.

Supporting information

S1 Fig. Differences in the total movement between differently treated zebrafish in 5-minute time intervals (Mann-Whitney U test).

(TIF)

S1 Table. Linear regression values of the treated groups during the 9 trials.

(DOCX)

Data Availability

All MS Excel files are available from the EBI database (accession number: S-BSST1111) at https://www.ebi.ac.uk/biostudies/studies/S-BSST1111.

Funding Statement

This work was supported by the Medical Research Council UK (grant number G1001235) and European Union’s Horizon 2020 OPEN FET RIA (NEURAM, No, 712821).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Liu J, Baraban SC. Network Properties Revealed during Multi-Scale Calcium Imaging of Seizure Activity in Zebrafish. eneuro. 2019;6(1):ENEURO.0041–19. doi: 10.1523/ENEURO.0041-19.2019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Baraban SC, Taylor MR, Castro PA, Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience. 2005;131(3):759–68. doi: 10.1016/j.neuroscience.2004.11.031 . [DOI] [PubMed] [Google Scholar]
  • 3.Yang X, Lin J, Peng X, Zhang Q, Zhang Y, Guo N, et al. Effects of picrotoxin on zebrafish larvae behaviors: A comparison study with PTZ. Epilepsy Behav. 2017;70(Pt A):224–31. Epub 20170422. doi: 10.1016/j.yebeh.2017.03.023 . [DOI] [PubMed] [Google Scholar]
  • 4.Afrikanova T, Serruys A-SK, Buenafe OEM, Clinckers R, Smolders I, De Witte PAM, et al. Validation of the Zebrafish Pentylenetetrazol Seizure Model: Locomotor versus Electrographic Responses to Antiepileptic Drugs. PLoS ONE. 2013;8(1):e54166. doi: 10.1371/journal.pone.0054166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Stewart AM, Ullmann JFP, Norton WHJ, Parker MO, Brennan CH, Gerlai R, et al. Molecular psychiatry of zebrafish. Molecular Psychiatry. 2015;20(1):2–17. doi: 10.1038/mp.2014.128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hortopan GA, Dinday MT, Baraban SC. Spontaneous Seizures and Altered Gene Expression in GABA Signaling Pathways in a mind bomb Mutant Zebrafish. Journal of Neuroscience. 2010;30(41):13718–28. doi: 10.1523/JNEUROSCI.1887-10.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tegelenbosch RAJ, Noldus LPJJ, Richardson MK, Ahmad F. Zebrafish embryos and larvae in behavioural assays. Behaviour. 2012;149(10–12):1241–81. doi: 10.1163/1568539X-00003020 [DOI] [Google Scholar]
  • 8.Pelkowski SD, Kapoor M, Richendrfer HA, Wang X, Colwill RM, Creton R. A novel high-throughput imaging system for automated analyses of avoidance behavior in zebrafish larvae. Behavioural Brain Research. 2011;223(1):135–44. doi: 10.1016/j.bbr.2011.04.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Joo W, Vivian MD, Graham BJ, Soucy ER, Thyme SB. A Customizable Low-Cost System for Massively Parallel Zebrafish Behavioral Phenotyping. Front Behav Neurosci. 2020;14:606900. Epub 20210118. doi: 10.3389/fnbeh.2020.606900 ; PubMed Central PMCID: PMC7847893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Shaw PAG, Panda SK, Stanca A, Luyten W. Optimization of a locomotion-based zebrafish seizure model. J Neurosci Methods. 2022;375:109594. Epub 20220411. doi: 10.1016/j.jneumeth.2022.109594 . [DOI] [PubMed] [Google Scholar]
  • 11.Sarkisian MR. Overview of the Current Animal Models for Human Seizure and Epileptic Disorders. Epilepsy Behav. 2001;2(3):201–16. doi: 10.1006/ebeh.2001.0193 . [DOI] [PubMed] [Google Scholar]
  • 12.Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6(9):793–804. doi: 10.1016/S1474-4422(07)70215-6 . [DOI] [PubMed] [Google Scholar]
  • 13.Wahab A. Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development. Pharmaceuticals (Basel). 2010;3(7):2090–110. Epub 20100705. doi: 10.3390/ph3072090 ; PubMed Central PMCID: PMC4036655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Gawel K, Langlois M, Martins T, van der Ent W, Tiraboschi E, Jacmin M, et al. Seizing the moment: Zebrafish epilepsy models. Neurosci Biobehav Rev. 2020;116:1–20. Epub 20200613. doi: 10.1016/j.neubiorev.2020.06.010 . [DOI] [PubMed] [Google Scholar]
  • 15.MacPhail RC, Brooks J, Hunter DL, Padnos B, Irons TD, Padilla S. Locomotion in larval zebrafish: Influence of time of day, lighting and ethanol. Neurotoxicology. 2009;30(1):52–8. Epub 20081005. doi: 10.1016/j.neuro.2008.09.011 . [DOI] [PubMed] [Google Scholar]
  • 16.Peng X, Lin J, Zhu Y, Liu X, Zhang Y, Ji Y, et al. Anxiety-related behavioral responses of pentylenetetrazole-treated zebrafish larvae to light-dark transitions. Pharmacol Biochem Behav. 2016;145:55–65. Epub 20160324. doi: 10.1016/j.pbb.2016.03.010 . [DOI] [PubMed] [Google Scholar]
  • 17.Johan Arief MF, Choo BKM, Yap JL, Kumari Y, Shaikh MF. A Systematic Review on Non-mammalian Models in Epilepsy Research. Front Pharmacol. 2018;9:655. Epub 20180627. doi: 10.3389/fphar.2018.00655 ; PubMed Central PMCID: PMC6030834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Vermoesen K, Serruys AS, Loyens E, Afrikanova T, Massie A, Schallier A, et al. Assessment of the convulsant liability of antidepressants using zebrafish and mouse seizure models. Epilepsy Behav. 2011;22(3):450–60. Epub 20111001. doi: 10.1016/j.yebeh.2011.08.016 . [DOI] [PubMed] [Google Scholar]
  • 19.Kandratavicius L, Balista P, Lopes-Aguiar C, Ruggiero R, Umeoka E, Garcia-Cairasco N, et al. Animal models of epilepsy: use and limitations. Neuropsychiatric Disease and Treatment. 2014:1693. doi: 10.2147/NDT.S50371 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Curia G, Longo D, Biagini G, Jones RS, Avoli M. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods. 2008;172(2):143–57. Epub 20080426. doi: 10.1016/j.jneumeth.2008.04.019 ; PubMed Central PMCID: PMC2518220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Paudel YN, Kumari Y, Abidin SAZ, Othman I, Shaikh MF. Pilocarpine Induced Behavioral and Biochemical Alterations in Chronic Seizure-Like Condition in Adult Zebrafish. International Journal of Molecular Sciences. 2020;21(7):2492. doi: 10.3390/ijms21072492 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Maximino C, Herculano AM. A review of monoaminergic neuropsychopharmacology in zebrafish. Zebrafish. 2010;7(4):359–78. doi: 10.1089/zeb.2010.0669 . [DOI] [PubMed] [Google Scholar]
  • 23.Hammer Ø, Harper DAT, Ryan PD. Past: Paleontological Statistics Software Package for Education and Data Analysis. Palaeontologia Electronica. 2001;4(1):9pp. [Google Scholar]
  • 24.Prober DA, Rihel J, Onah AA, Sung RJ, Schier AF. Hypocretin/Orexin Overexpression Induces An Insomnia-Like Phenotype in Zebrafish. Journal of Neuroscience. 2006;26(51):13400–10. doi: 10.1523/JNEUROSCI.4332-06.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Padilla S, Hunter DL, Padnos B, Frady S, MacPhail RC. Assessing locomotor activity in larval zebrafish: Influence of extrinsic and intrinsic variables. Neurotoxicol Teratol. 2011;33(6):624–30. Epub 20110816. doi: 10.1016/j.ntt.2011.08.005 . [DOI] [PubMed] [Google Scholar]
  • 26.Hong Y, Luo Y. Zebrafish Model in Ophthalmology to Study Disease Mechanism and Drug Discovery. Pharmaceuticals. 2021;14(8):716. doi: 10.3390/ph14080716 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Emina MO. Aging and topical pilocarpine concentrations effects on pupil size and tear flow rate. Journal of Optometry. 2010;3(2):102–6. doi: 10.1016/S1888-4296(10)70014-5 [DOI] [Google Scholar]
  • 28.Jian J, Lin J, Liu X-y, Ying-lan Z, Li F, Wang F, et al. The effects of pilocarpine on locomotor activities and anxiety-related behavior of zebrafish larvae under different illumination conditions. Fudan University Journal of Medical Science. 2019;46(05):667–75,86. doi: 10.3969/j.issn.1672-8467.2019.05.016 [DOI] [Google Scholar]
  • 29.Tønnesen HH. Formulation and stability testing of photolabile drugs. Int J Pharm. 2001;225(1–2):1–14. doi: 10.1016/s0378-5173(01)00746-3 . [DOI] [PubMed] [Google Scholar]
  • 30.Lopes MW, Sapio MR, Leal RB, Fricker LD. Knockdown of Carboxypeptidase A6 in Zebrafish Larvae Reduces Response to Seizure-Inducing Drugs and Causes Changes in the Level of mRNAs Encoding Signaling Molecules. PLOS ONE. 2016;11(4):e0152905. doi: 10.1371/journal.pone.0152905 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Eddins D, Cerutti D, Williams P, Linney E, Levin ED. Zebrafish provide a sensitive model of persisting neurobehavioral effects of developmental chlorpyrifos exposure: Comparison with nicotine and pilocarpine effects and relationship to dopamine deficits. Neurotoxicology and Teratology. 2010;32(1):99–108. doi: 10.1016/j.ntt.2009.02.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Huang RQ, Bell-Horner CL, Dibas MI, Covey DF, Drewe JA, Dillon GH. Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: mechanism and site of action. J Pharmacol Exp Ther. 2001;298(3):986–95. . [PubMed] [Google Scholar]
  • 33.Priel MR, Albuquerque EX. Short-Term Effects of Pilocarpine on Rat Hippocampal Neurons in Culture. Epilepsia. 2002;43:40–6. doi: 10.1046/j.1528-1157.43.s.5.18.x [DOI] [PubMed] [Google Scholar]
  • 34.Smolders I, Khan GM, Manil J, Ebinger G, Michotte Y. NMDA receptor-mediated pilocarpine-induced seizures: characterization in freely moving rats by microdialysis. British Journal of Pharmacology. 1997;121(6):1171–9. doi: 10.1038/sj.bjp.0701231 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Nagao T, Alonso A, Avoli M. Epileptiform activity induced by pilocarpine in the rat hippocampal-entorhinal slice preparation. Neuroscience. 1996;72(2):399–408. doi: 10.1016/0306-4522(95)00534-x . [DOI] [PubMed] [Google Scholar]
  • 36.Baxendale S, Holdsworth CJ, Meza Santoscoy PL, Harrison MRM, Fox J, Parkin CA, et al. Identification of compounds with anti-convulsant properties in a zebrafish model of epileptic seizures. Disease Models & Mechanisms. 2012;5(6):773–84. doi: 10.1242/dmm.010090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Orellana-Paucar AM, Serruys A-SK, Afrikanova T, Maes J, De Borggraeve W, Alen J, et al. Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in zebrafish and mouse seizure models. Epilepsy & Behavior. 2012;24(1):14–22. doi: 10.1016/j.yebeh.2012.02.020 [DOI] [PubMed] [Google Scholar]
  • 38.Rahn JJ, Bestman JE, Josey BJ, Inks ES, Stackley KD, Rogers CE, et al. Novel Vitamin K analogs suppress seizures in zebrafish and mouse models of epilepsy. Neuroscience. 2014;259:142–54. doi: 10.1016/j.neuroscience.2013.11.040 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Challal S, Buenafe OEM, Queiroz EF, Maljevic S, Marcourt L, Bock M, et al. Zebrafish Bioassay-Guided Microfractionation Identifies Anticonvulsant Steroid Glycosides from the Philippine Medicinal Plant Solanum torvum. ACS Chemical Neuroscience. 2014;5(10):993–1004. doi: 10.1021/cn5001342 [DOI] [PubMed] [Google Scholar]
  • 40.Liu M, Copmans D, Lu JG, Yang MR, Sourbron J, Ny A, et al. Bioassay-guided isolation of anti-seizure principles from Semen Pharbitidis using a zebrafish pentylenetetrazol seizure model. J Ethnopharmacol. 2019;232:130–4. Epub 20181217. doi: 10.1016/j.jep.2018.12.024 . [DOI] [PubMed] [Google Scholar]
  • 41.Moradi-Afrapoli F, Ebrahimi SN, Smiesko M, Hamburger M. HPLC-Based Activity Profiling for GABA(A) Receptor Modulators in Extracts: Validation of an Approach Utilizing a Larval Zebrafish Locomotor Assay. J Nat Prod. 2017;80(5):1548–57. Epub 20170509. doi: 10.1021/acs.jnatprod.7b00081 . [DOI] [PubMed] [Google Scholar]
  • 42.Nieoczym D, Socała K, Gawel K, Esguerra CV, Wyska E, Wlaź P. Anticonvulsant Activity of Pterostilbene in Zebrafish and Mouse Acute Seizure Tests. Neurochemical Research. 2019;44(5):1043–55. doi: 10.1007/s11064-019-02735-2 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Giuseppe Biagini

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

10 May 2023

PONE-D-23-10135A comparative study to optimize experimental conditions of pentylenetetrazol and pilocarpine-induced epilepsy in zebrafish larvaePLOS ONE

Dear Dr. Sik,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jun 24 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Giuseppe Biagini, MD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The zebrafish model is widely used to study the effects of anti-epileptic drugs. However, according to Szep et al, the methods used are often not sufficiently detailed, which leads to results discrepancies between laboratories. In their paper, they performed a series of experiments to optimise the zebrafish epilepsy model and found that the zebrafish larvae move significantly more in the light condition compared to the dark condition, independently of treatment with PTZ or pilocarpine. When examining the optimal observation time, the found that the during the half-hour period, the first 5 minutes were found to be the most different from the others. They therefore recommend 30 minutes of drug pre-treatment followed by a 10-minute test in light conditions with a 5-minute accommodation time. For testing of photolabile AED compound candidates, they recommend the pilocarpine test in the dark. Investigators in the field of epilepsy could benefit from such a refinement of the zebrafish model.

Asbtract

The use of term “epileptics” is not the right term to use. If authors refer to PTZ or pilocarpine, it should be “chemoconvulsants” or “convulsants”.

Materials and Methods

We left the fish in the solution for 30 for accommodation before starting the recording 10. Please correct. 30 s or min?

The Results section should be re-organized. Figure legends should not be placed in the text. Moreover, results of statistical tests are provided in the first paragraph of the Results section but are missing in the following sections.

Discussion

“Zebrafish have diurnal activity, meaning they are more active in the morning and less active at night…”. I think that the term “diurnal” refers to active periods during the day, not only in the morning.

Reviewer #2: The paper entitled “A comparative study to optimize experimental conditions of pentylenetetrazol and pilocarpine-induced epilepsy in zebrafish larvae” by David Szep et.al. describes a series of experiments finalized to the optimization and standardization of the zebrafish larvae epilepsy models of Pentylenetetrazol and pilocarpine to support the development of new anti-epileptic drugs.

The authors describe the steps applied to execute the experiments, how they have analyzed the data and how their findings support their recommendations. The figures are generally well described and easy to understand. Moreover, the recommended method provides an easy readout, the larvae movement, it is a high-throughput technique and a replacement method since it uses not independently feeding larval forms.

Minor issues

Introduction

Line 11: the authors report; “Until 5 dpf larvae is not considered an animal”. According to the Directive 2010/63/EU the law is applicable on the independently feeding larval forms. The housing/rising temperature should also reported since the age at which zebrafish larvea become indipendently feeding forms depends on this parameter.

Materials and methods

The authors should also report in the material and methods:

• the zebrafish strain that they have used to generate the embryos;

• the housing condition of the zebrafish

• the mating system to obtain the zebrafish embryos;

• the incubation/housing conditions of the larvae before the experiments.

Line 3: the authors should also report the recipe of the egg water or quote a publication where is reported;

Line 4: the authors should state in which solvent the drugs are diluted.

Line 6: the authors should add the word “minutes” after “the solution for 30”

Line 9: the authors should write the accommodation time as reported in the Figure 1.

Line 9: “90 fish were moved into a 96 well plate”. The authors should specify if they have placed 30 control, 30 PTZ and 30 pilocarpine treated larvae in each 96 well plate. It is not stated in the manuscript.

Line 19: “we set up a 0.2 % threshold and excluded the remaining data”. The authors should explain what they have done.

Line 25: the authors should describe which method they have used to detect the outlier and what they have considered as an outlier.

Line 26: The authors should consider the use of the Kruskall Wallis test when comparing more than 2 independent groups at the same time (e.g. Fig 4). Mann Whitney U test is suitable for comparing 2 independent groups.

Results

Fig. 4: The authors should state the origin of the data reported in the Figure 4.

Fig. 6: There are 8 white bars instead of 9 bars representing the value for each trial.

Line 34-38 “We also performed a linear regression analysis with the cumulative values of the distance moved during the time intervals to assess if longer observation time could impact the difference between the groups. As seen in Fig 7 by increasing the time, the distances changed proportionally within the groups. This was supported by the linear regression analysis in most of the cases according to the R2 values (S2 Fig).”

The authors to support this statement should assess the possible difference among the regression coefficients (β) of the regression lines calculated for the control, the PTZ and the Pilocarpine groups through a hypothesis test.

Moreover, to support the above statement, the authors should also add a figure showing the regression lines calculated for the control, the PTZ and the Pilocarpine groups.

Discussion

Line 50. “We suggest that the recording algorithm has some feature that makes the first 5 minutes of recording unreliable, and thus needs to be disregarded.”

The author should double check with the recording algorithm maker

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jul 28;18(7):e0288904. doi: 10.1371/journal.pone.0288904.r002

Author response to Decision Letter 0


5 Jun 2023

Dear Editors,

We would like to thank the reviewers for their time and very detailed and extremely useful comments on the manuscript. We have corrected the manuscript to address their concerns.

We believe that the manuscript is now suitable for publication in Plos One.

Reviewer #1:

The zebrafish model is widely used to study the effects of anti-epileptic drugs. However, according to Szep et al, the methods used are often not sufficiently detailed, which leads to results discrepancies between laboratories. In their paper, they performed a series of experiments to optimise the zebrafish epilepsy model and found that the zebrafish larvae move significantly more in the light condition compared to the dark condition, independently of treatment with PTZ or pilocarpine. When examining the optimal observation time, they found that during the half-hour period, the first 5 minutes were found to be the most different from the others. They therefore recommend 30 minutes of drug pre-treatment followed by a 10-minute test in light conditions with a 5-minute accommodation time. For testing photolabile AED compound candidates, they recommend the pilocarpine test in the dark. Investigators in the field of epilepsy could benefit from such a refinement of the zebrafish model.

Abstract

The use of term “epileptics” is not the right term to use. If authors refer to PTZ or pilocarpine, it should be “chemoconvulsants” or “convulsants”.

Thank you for your suggestion, we corrected the revised manuscript and used “convulsant” instead of “epileptics”.

Materials and Methods

We left the fish in the solution for 30 for accommodation before starting the recording 10. Please correct. 30 s or min?

Thank you for the comment, it is supposed to be 30 minutes, we corrected it.

The Results section should be re-organized. Figure legends should not be placed in the text.

Thank you for your suggestion, we reorganized as recommended. We removed the figure legends from the text, and placed them to the end, as suggested by the Submission Guidelines.

Moreover, the results of statistical tests are provided in the first paragraph of the Results section but are missing in the following sections.

There would be too many statistical results in the last sections, so in order to read easier the results of the statistical tests are placed into Table 1, S1 FIG, and S1 Table.

Discussion

“Zebrafish have diurnal activity, meaning they are more active in the morning and less active at night…”. I think that the term “diurnal” refers to active periods during the day, not only in the morning.

We appreciate the comment and corrected the sentence in the following way: “Zebrafish have diurnal activity, meaning they are more active during the day and less active at night.”

Reviewer #2:

The paper entitled “A comparative study to optimize experimental conditions of pentylenetetrazol and pilocarpine-induced epilepsy in zebrafish larvae” by David Szep et.al. describes a series of experiments finalized to the optimization and standardization of the zebrafish larvae epilepsy models of Pentylenetetrazol and pilocarpine to support the development of new anti-epileptic drugs.

The authors describe the steps applied to execute the experiments, how they have analyzed the data and how their findings support their recommendations. The figures are generally well described and easy to understand. Moreover, the recommended method provides an easy readout, the larvae movement, it is a high-throughput technique and a replacement method since it uses not independently feeding larval forms.

Line 11: the authors report; ““Until 5 dpf larvae is not considered an animal”. According to the Directive 2010/63/EU the law is applicable on the independently feeding larval forms. The housing/rising temperature should also be reported since the age at which zebrafish larvae become independent feeding forms depends on this parameter.

Thank you for your suggestion. The larvae that we used for the experiments did not reach the independent feeding form. To be clear we corrected the sentence in the introduction as the following: “As zebrafish larva starts to feed at 5 days post fertilization (dpf) and according to regulations the nonfeeding larva is not considered an animal, thus ethical permit is not required for performing experiments on ≤ 5dpf zebrafish larvae. Hence zebrafish larvae can be considered as a non-animal in vivo vertebrate model.”

Materials and methods

The authors should also report in the material and methods:

• the zebrafish strain that they have used to generate the embryos;

• the housing condition of the zebrafish

• the mating system to obtain the zebrafish embryos;

• the incubation/housing conditions of the larvae before the experiments.

Line 3: the authors should also report the recipe of the egg water or quote a publication where is reported;

Line 4: the authors should state in which solvent the drugs are diluted.

Line 6: the authors should add the word “minutes” after “the solution for 30”

Line 9: the authors should write the accommodation time as reported in the Figure 1.

Line 9: “90 fish were moved into a 96 well plate”. The authors should specify if they have placed 30 control, 30 PTZ and 30 pilocarpine treated larvae in each 96 well plate. It is not stated in the manuscript.

Line 19: “we set up a 0.2 % threshold and excluded the remaining data”. The authors should explain what they have done.

Line 25: the authors should describe which method they have used to detect the outlier and what they have considered as an outlier.

We extended the Material and methods part with the missing information.

Line 26: The authors should consider the use of the Kruskall Wallis test when comparing more than 2 independent groups at the same time (e.g. Fig 4). Mann Whitney U test is suitable for comparing 2 independent groups.

We indeed performed Kruskall-Wallis tests during the initial analysis which resulted in very similar results to Mann-Whitney U test. K-W test shows us that there is at least one group that is different from the others, but we were more interested in which one is different. We had the option to use Dunn’s post hoc test along with the K-W test or the M-W U test alone. We chose the M-W U test because in it is more straightforward and gave identical statistical significance to K-W.

Results

Fig. 4: The authors should state the origin of the data reported in the Figure 4.

To create the figures, we used our experimental data. In Figure 4, the significant differences were the result of the Mann-Whitney U test. We extended the figure legends with the name of the test we used.

Fig. 6: There are 8 white bars instead of 9 bars representing the value for each trial.

Thank you for your observation, one row of data was missing, we corrected it in the revised manuscript.

Line 34-38: “We also performed a linear regression analysis with the cumulative values of the distance moved during the time intervals to assess if longer observation time could impact the difference between the groups. As seen in Fig 7 by increasing the time, the distances changed proportionally within the groups. This was supported by the linear regression analysis in most of the cases according to the R2 values (S2 Fig).”

The authors to support this statement should assess the possible difference among the regression coefficients (β) of the regression lines calculated for the control, the PTZ and the Pilocarpine groups through a hypothesis test.

Moreover, to support the above statement, the authors should also add a figure showing the regression lines calculated for the control, the PTZ and the Pilocarpine groups.

Thank you for your suggestion, we created a new figure (Figure 8) showing the regression lines, among the missing regression coefficients (β) values.

Discussion

Line 50. “We suggest that the recording algorithm has some feature that makes the first 5 minutes of recording unreliable, and thus needs to be disregarded.”

The author should double check with the recording algorithm maker.

We indeed contacted the software developer company when we first observed this peculiar problem. After several lengthy discussions, they were unable to identify the reason for this reproducible observation. Since we are not in a position to find the real cause, we left the text in the manuscript as an observation and recommendation to avoid errors in the analysis without an explanation for the observation.

Finally, we would like to thank the reviewers and editors for evaluating our manuscript. We corrected all errors and followed the reviewers’ suggestions which certainly greatly improved the quality of the manuscript.

Attachment

Submitted filename: Rebuttal letter.docx

Decision Letter 1

Giuseppe Biagini

6 Jul 2023

A comparative study to optimize experimental conditions of pentylenetetrazol and pilocarpine-induced epilepsy in zebrafish larvae

PONE-D-23-10135R1

Dear Dr. Sik,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Giuseppe Biagini, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Acceptance letter

Giuseppe Biagini

20 Jul 2023

PONE-D-23-10135R1

A comparative study to optimize experimental conditions of pentylenetetrazol and pilocarpine-induced epilepsy in zebrafish larvae

Dear Dr. Sik:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Giuseppe Biagini

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Differences in the total movement between differently treated zebrafish in 5-minute time intervals (Mann-Whitney U test).

    (TIF)

    S1 Table. Linear regression values of the treated groups during the 9 trials.

    (DOCX)

    Attachment

    Submitted filename: Rebuttal letter.docx

    Data Availability Statement

    All MS Excel files are available from the EBI database (accession number: S-BSST1111) at https://www.ebi.ac.uk/biostudies/studies/S-BSST1111.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES